Intellect Neurosciences, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Intellect Neurosciences, Inc.
Isofol And 4D - A Sorry Tale Of Two Battered Biotechs
The fear of going out of business before getting a drug submitted to regulators is one that a couple of European biotechs have had to face up to this week.
Financing Quarterly Statistics, Q3 2022
During Q3, biopharmas brought in an aggregate $18.1bn in financing and device company fundraising totaled $5.1bn; while in vitro diagnostic firms and research tools players raised $771m.
Does The SPAC Have A Future In Biopharma?
Special purpose acquisition companies can bring biopharma firms to market faster than a traditional initial public offering, but frequent failures and increased scrutiny from the US Securities and Exchange Commission mean their heyday in the life sciences space is arguably over.
Stock Watch: Debt And Biotech Do Not Mix
Even with higher interest rates, some debt on the balance sheets of profitable biotechs is healthy. However, among loss-making biotechs and in the current environment, raising new debt has unhealthy connotations.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice